Cargando…

Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review)

Concurrent chemoradiotherapy (CHRT) remains the therapeutic standard for locally advanced inoperable non-small-cell lung cancer (NSCLC). The median overall survival (OS) with this approach is in the range of 20–30 months, with five-year survival of approximately 30%. These outcomes have recently bee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Łazar-Poniatowska, Małgorzata, Bandura, Artur, Dziadziuszko, Rafał, Jassem, Jacek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Article on Radiotherapy in Thoracic Malignancies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107727/ https://www.ncbi.nlm.nih.gov/pubmed/34012811 http://dx.doi.org/10.21037/tlcr-20-704

Ejemplares similares

Radiotherapy in thoracic malignancies: the preface
por: Jassem, Jacek, et al.
Publicado: (2021)

Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents
por: Wrona, Anna, et al.
Publicado: (2021)

Tumour motion management in lung cancer: a narrative review
por: Botticella, Angela, et al.
Publicado: (2021)

Thoracic radiotherapy in small cell lung cancer—a narrative review
por: Levy, Antonin, et al.
Publicado: (2021)

Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists
por: Glatzer, Markus, et al.
Publicado: (2021)

Prophylactic cranial irradiation in SCLC
por: Suwinski, Rafal
Publicado: (2021)

Stereotactic radiotherapy for early stage non-small cell lung cancer: current standards and ongoing research
por: Vlaskou Badra, Eugenia, et al.
Publicado: (2021)

Palliative radiotherapy indications during the COVID-19 pandemic and in future complex logistic settings: the NORMALITY model
por: Cellini, Francesco, et al.
Publicado: (2021)

Contralateral esophageal sparing technique in definitive radiotherapy for non-small cell lung cancer: dosimetric parameters and normal tissue complication probability modeling
por: Łazar-Poniatowska, Małgorzata, et al.
Publicado: (2022)

Radiotherapy for thymic epithelial tumours: a review
por: Süveg, Krisztian, et al.
Publicado: (2021)

Challenges in the target volume definition of lung cancer radiotherapy
por: Mercieca, Susan, et al.
Publicado: (2021)

Dose and fractionation schedules in radiotherapy for non-small cell lung cancer
por: Kepka, Lucyna, et al.
Publicado: (2021)

Evolving target volume concepts in locally advanced non-small cell lung cancer
por: Nestle, Ursula, et al.
Publicado: (2021)

An overview of the published and running randomized phase 3 clinical results of radiotherapy in combination with immunotherapy
por: Vanneste, Ben G. L., et al.
Publicado: (2021)

Preoperative and postoperative radiotherapy (RT) for non-small cell lung cancer: still an open question
por: Van Houtte, Paul, et al.
Publicado: (2021)

Controversies in the role of radiotherapy in pleural mesothelioma
por: Hanna, Gerard G., et al.
Publicado: (2021)

P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England
por: Jones, David, et al.
Publicado: (2022)

Positional Accuracy of Treating Multiple Versus Single Vertebral Metastases With Stereotactic Body Radiotherapy
por: Chang, Joe H., et al.
Publicado: (2016)

Dosimetric Comparison and Evaluation of 4 Stereotactic Body Radiotherapy Techniques for the Treatment of Prostate Cancer
por: Seppälä, Jan, et al.
Publicado: (2016)

Changes in Tumor Volumes and Spatial Locations Relative to Normal Tissues During Cervical Cancer Radiotherapy Assessed by Cone Beam Computed Tomography
por: Chen, Wenjuan, et al.
Publicado: (2017)

Delta radiomics for rectal cancer response prediction with hybrid 0.35 T magnetic resonance-guided radiotherapy (MRgRT): a hypothesis-generating study for an innovative personalized medicine approach
por: Boldrini, Luca, et al.
Publicado: (2018)

A snapshot on radiotherapy for head and neck cancer patients during the COVID-19 pandemic: a survey of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) head and neck working group
por: De Felice, Francesca, et al.
Publicado: (2020)

Weekly hypofractionated radiation therapy in elderly non-resectable cutaneous squamous cell carcinoma of the head and neck region
por: De Felice, Francesca, et al.
Publicado: (2020)

Impact of COVID-19 on workload burden of a complex radiotherapy facility
por: Francolini, Giulio, et al.
Publicado: (2021)

Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients
por: Detti, Beatrice, et al.
Publicado: (2021)

ESTRO vision 2030: the young Italian Association of Radiotherapy and Clinical Oncology (yAIRO) commitment statement
por: De Felice, Francesca, et al.
Publicado: (2021)

Impact on mental health of the COVID-19 pandemic in a radiation oncology department
por: Caliandro, Morena, et al.
Publicado: (2022)

Stereotactic or conventional radiotherapy for macroscopic prostate bed recurrence: a propensity score analysis
por: Francolini, Giulio, et al.
Publicado: (2022)

Stereotactic ablative body radiotherapy (SABR) lung fractionations locally in the COVID-19 era and the impact on dosimetry, resources, early toxicities, and the environment
por: Phelps, Lyndsey, et al.
Publicado: (2021)

EROS 2.0 study: evaluation of two interventional radiotherapy (brachytherapy) schedules for endometrial cancer: a comparison of late vaginal toxicity rates
por: Lancellotta, Valentina, et al.
Publicado: (2022)

The impact of particle radiotherapy on the functioning of cardiac implantable electronic devices: a systematic review of in vitro and in vivo studies according to PICO criteria
por: Barcellini, Amelia, et al.
Publicado: (2022)

Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719)
por: Francolini, Giulio, et al.
Publicado: (2022)

P096: Polymorphisms in SETD7 may predispose the risk of developing late cardiac side effects after radiotherapy including the mediastinum in Hodgkin’ s lymphoma.
por: Linderoth, Johan, et al.
Publicado: (2022)

P092: Estimating the dosimetric benefit of involved-node radiotherapy in comparison to involved-field radiotherapy - implications from the GHSG HD 17 trial
por: Oertel, Michael, et al.
Publicado: (2022)

P091: Early analysis of the PRO-Hodgkin study: Clinical investigation of pencil beam scanning proton treatment in Hodgkin lymphoma patients
por: Goldkuhl, Christina, et al.
Publicado: (2022)

P093: From involved- field to involved-node – Quality analysis of the radiation therapy in HD 17 by the expert panel of the German Hodgkin Study Group
por: Oertel, Michael, et al.
Publicado: (2022)

P094: Long-term outcomes of bulky classic Hodgkin lymphoma managed with a PET-adapted approach demonstrate excellent outcomes in PET-negative cases
por: Kim, Jowon Laura, et al.
Publicado: (2022)

P097: The status quo of involved-field radiotherapy – Quality analysis of radiotherapy in the GHSG HD 16
por: Oertel, Michael, et al.
Publicado: (2022)

Magnetic resonance-guided stereotactic body radiation therapy (MRgSBRT) for oligometastatic patients: a single-center experience
por: Chiloiro, Giuditta, et al.
Publicado: (2023)

Real world experience of hypofractionated radical radiotherapy for non-small cell lung cancer (NSCLC) during the COVID-19 pandemic: a well-tolerated radiotherapy schedule with acceptable progression-free (PFS) and overall survival (OS)
por: Jeyin, Nidhish, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d2kbmv0dksdegmpejh0j3iv28f